AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20186637
Drug: Forgiveness intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Forgiveness intervention (10 weekly interpersonal forgiveness therapy sessions)
Trial: 20186637
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (10 weekly sessions)
Trial: 7908357
Drug: c7E3 bolus/c7E3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c7E3 bolus/c7E3 infusion
Trial: 7908357
Drug: c7E3 bolus/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c7E3 bolus/placebo infusion
Trial: 3047338
Drug: Vincristine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine (1 mg/m2) and prednisone (0.6 mg/kg/d for seven days at 8-week intervals)
Trial: 26936139
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g high molecular weight (HMW) β‐glucan/d
Trial: 26936139
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g low molecular weight (LMW) β‐glucan/d
Trial: 26936139
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g low molecular weight (LMW) β‐glucan/d
Trial: 22985900
Drug: Topical analgesic
RxNorm normalized name: Tricylate 2%-10% Topical Analgesic Cream
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical analgesic patches
Trial: 22985900
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug patches (control)
Trial: 22985900
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medial and lateral prefrontal functional connections
Trial: 18025650
Drug: Topical antiglaucoma
RxNorm normalized name: ANTIGLAUCOMA MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antiglaucoma agents
Trial: 10687264
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy (amoxicillin at 500 mg twice a day for 14 days, metronidazole at 500 mg twice a day for 10 days, omeprazole at 20 mg twice a day for 20 days)
Trial: 30070398
Drug: Imagery Rehearsal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imagery Rehearsal Therapy + Cognitive Behavioral Therapy (IRT + CBT)
Trial: 26991889
Drug: Exercise augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise augmentation of treatment as usual (part of STRIDE trial)
Trial: 26991889
Drug: Cocaine plus
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine plus other stimulant use disorders
Trial: 20799973
Drug: Multifaceted community-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted community-based care program including facilitated bone mineral density testing, patient education, and patient-specific recommendations for osteoporosis treatment.
Trial: 7573781
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of ethanol (0.5 g/kg)
Trial: 2333581
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment with vincristine, daunorubicin, prednisone, cytosine arabinoside, and 6-thioguanine; followed by consolidation treatment with VM-26, cyclophosphamide, BCNU, and L-asparaginase; CNS prophylaxis with intrathecal methotrexate.
Trial: 2333581
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy for remaining patients.
Trial: 2333581
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment including chemotherapy and BMT.
Trial: 17557044
Drug: Endoscopic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic therapies (endoscopic mucosal resection, ablative therapies)
Trial: 17557044
Drug: Mainstays of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainstays of treatment for advanced cancers (debulking surgery, chemotherapy, radiotherapy, palliative care)
Trial: 8196849
Drug: Naproxen 1000
RxNorm normalized name: naproxen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 1000 mg/day
Trial: 11253158
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg/day, 400 mg/day)
Trial: 9167210
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) infusion at 30 ng/kg/min for 48 hours
Trial: 23071528
Drug: Sirolimus (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (1.3 to 1.5 mg per day for a median of 19 months)
Trial: 14968218
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg thrice daily for 5 days
Trial: 14968218
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg thrice daily for 5 days followed by alpha-tocopherol 200 mg thrice daily for another 5 days
Trial: 4003099
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Org 3770
Trial: 4003099
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg Org 3770
Trial: 4003099
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Org 3770
Trial: 30606225
Drug: Chiropractic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic manipulative therapy (CMT) - four treatments over a 2-week period
Trial: 30606225
Drug: Wait-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list control - no treatment during the 2-week period
Trial: 24867903
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy and exercise program
Trial: 22835512
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of systemic antihypertensives
Trial: 17555427
Drug: Mitemcinal 10
RxNorm normalized name: Mitemcinal
DrugBank: Mitemcinal (DB06587)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitemcinal 10 mg
Trial: 15702239
Drug: Shoyu polysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shoyu polysaccharides (SPS) 600 mg daily
Trial: 9395621
Drug: HP-200 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-200 (7.5 g sachet mixed with water, orally)
Trial: 1715501
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (4 IU/m2 per day) for 6 months
Trial: 14624765
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 6 months
Trial: 6857511
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate solution (RL, 130 mEq sodium/L, 274 mOsm/L)
Trial: 6857511
Drug: Hypertonic balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic balanced salt solution (HSL, 250 mEq sodium/L, 514 mOsm/L)
Trial: 25669236
Drug: Standard cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive behavioral therapy (SCBT)
Trial: 24121692
Drug: Water-based gel
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-based gel applied during speculum examination
Trial: 15878927
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (600 microg followed by 400 microg every 3 hours)
Trial: 9620907
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy alone (n = 71)
Trial: 9620907
Drug: Nutritional therapy
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional therapy in combination with anabolic steroid treatment (n = 67)
Trial: 23490255
Drug: Multivitamins (folic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamins (folic acid 0.8 mg, vitamin B6 10 mg, and vitamin B12 500 μg)
Trial: 22333695
Drug: Thimerosal-free trivalent
RxNorm normalized name: Thimerosal
DrugBank: Thimerosal (DB11590)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thimerosal-free trivalent inactivated influenza vaccine
Trial: 22333695
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (US-licensed influenza vaccine)
Trial: 9420639
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg coenzyme Q10 (CoQ10)
Trial: 2261301
Drug: Delayed excretion
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed excretion greater than 10 min
Trial: 2261301
Drug: No delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No delayed excretion
Trial: 7396058
Drug: Amoxicillin (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (375 mg, 3 times a day for 5 days)
Trial: 30901380
Drug: PF‐00547659 (anti-MAdCAM-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐00547659 (anti-MAdCAM-1 monoclonal antibody)
Trial: 21302687
Drug: Lidocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine spray 10%
Trial: 21302687
Drug: Tetracaine 2%
RxNorm normalized name: BENZOCAINE 14%/BUTAMBEN 2%/TETRACAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 2% solution
Trial: 18457617
Drug: Intensive preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive preventive program (quarterly examinations by general practitioner, treatment adjustments, lifestyle reinforcement)
Trial: 12437643
Drug: Normal HGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal HGF values (< 1.7 ng/ml, n = 69)
Trial: 12437643
Drug: Elevated HGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated HGF (≥ 1.7 ng/ml, n = 26)
Trial: 10599590
Drug: Biniwas (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biniwas (2 x 550 mg/day) for six months
Trial: 7861247
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (60 mg every 4 months; 30 mg for infants 6-11 months)
Trial: 6178567
Drug: Methisoprinol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methisoprinol (4 g/day per os in 4 divided doses for 2 weeks)
Trial: 30448878
Drug: Dark roast
RxNorm normalized name: Coffea arabica seed, roasted
DrugBank: Coffea arabica seed, roasted (DB15603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark roast coffee blend (500 ml per day)
Trial: 30448878
Drug: Water (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (500 ml per day)
Trial: 22975068
Drug: Ghrelin synthesis
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin synthesis administration
Trial: 22975068
Drug: Ghrelin replacement
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin replacement therapy during chemotherapy
Trial: 22975068
Drug: Ghrelin administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin administration for controlling postoperative cytokine storm
Trial: 19414681
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all‐trans retinoic acid (ATRA) and chemotherapy, maintenance treatment, escalating doses of cytarabine, early administration of dexamethasone, and CNS prophylaxis.
Trial: 19414681
Drug: Enrollment onto
RxNorm normalized name: Ontosein
DrugBank: Orgotein (DB11444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrollment onto the APL 2000 trial and combined maintenance with ATRA and chemotherapy.
Trial: 19414681
Drug: APL 93
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APL 93 trial (previous standard treatment).
Trial: 14535877
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg daily for 8 weeks
Trial: 7594328
Drug: Clarithromycin 200
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 200 mg twice daily for 2 weeks and Lansoprazole 30 mg daily for 8 weeks
Trial: 2890307
Drug: Continuous medication
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous medication
Trial: 1974743
Drug: Targeted medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted medication
Trial: 31069957
Drug: Vaginal insert
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal insert (tablet)
Trial: 27247202
Drug: Vaginal gel
RxNorm normalized name: VAGINAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel
Trial: 31069957
Drug: On-demand products
RxNorm normalized name: Gel-One Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand products (film, insert, gel)
Trial: 19967619
Drug: Pico-Salax (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pico-Salax (sodium picosulphate with magnesium citrate), administered in two doses: one the evening before and one on the morning of the procedure
Trial: 19967619
Drug: PEG‐ELS (polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐ELS (polyethylene glycol with electrolyte solution), administered over 4 hours
Trial: 15077265
Drug: Prednisone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (10 mg/day)
Trial: 8001300
Drug: K-strophanthin (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-strophanthin (0.125 mg intravenously)
Trial: 8001300
Drug: Digoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.25 mg orally)
Trial: 2968749
Drug: Prednisolone sodium
RxNorm normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone sodium tetrahydrophthalate followed by oral prednisone for 2 days
Trial: 2968749
Drug: Aldosterone followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone followed by oral 9 alpha fludrocortisone for 2 days
Trial: 27146798
Drug: Standard supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard supportive treatment (Control Group)
Trial: 24266309
Drug: Endoscopic hemoclips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic hemoclips therapy (group I)
Trial: 24266309
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of hemoclips and epinephrine (group II)
Trial: 16449027
Drug: rhIGF-I at
RxNorm normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIGF-I at 80 microg/kg body weight daily (n = 6)
Trial: 16449027
Drug: rhIGF-I at
RxNorm normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIGF-I at 40 microg/kg twice daily (n = 6)
Trial: 16449027
Drug: rhIGF-I at
RxNorm normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhIGF-I at 80 microg/kg twice daily (n = 6)
Trial: 12566183
Drug: Ambulatory epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory epidural analgesia (intermittent epidural injections of 0.1% ropivacaine with 0.6 microg/ml sufentanil)
Trial: 12566183
Drug: Non-ambulatory epidural
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ambulatory epidural analgesia (intermittent epidural injections of 0.1% ropivacaine with 0.6 microg/ml sufentanil)
Trial: 10693153
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of d,l‐fenfluramine (intervention group: bulimia nervosa remitted)
Trial: 10693153
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of d,l‐fenfluramine (intervention group: current bulimia nervosa)
Trial: 10984081
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg sublingual)
Trial: 30535217
Drug: 0.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg of oral alfacalcidol per day (intervention group; n=495)
Trial: 30535217
Drug: Treatment without
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment without vitamin D receptor activators (control group; n=481)
Trial: 12553505
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg meloxicam
Trial: 23648081
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil 50 mg (group FT)
Trial: 16906017
Drug: Alfentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil at concentrations of 0, 33.33, 66.67, and 100 ng/ml
Trial: 14516427
Drug: Combined surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined surgery group (360 degrees scleral buckling, pars plana vitrectomy, air-fluid exchange, endolaser, injection of 14% perfluoropropane gas)
Trial: 10905242
Drug: Regular inhaled
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular inhaled salbutamol 400 microg four times daily for 12 months
Trial: 10905242
Drug: Regular inhaled
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular inhaled salbutamol 400 microg four times daily
Trial: 9216092
Drug: TT5 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT5 (5 days treatment with furazolidone 600 mg/day, metronidazole 750 mg/day, amoxicillin 1.5 g/day)
Trial: 9216092
Drug: TT10 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT10 (10 days treatment with furazolidone 600 mg/day, metronidazole 750 mg/day, amoxicillin 1.5 g/day)
Trial: 6712199
Drug: Mezlocillin, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin, 4 g every 6 h
Trial: 6712199
Drug: Carbenicillin, 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenicillin, 7.5 g every 6 h
Trial: 6712199
Drug: Placebo, 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 0.9% NaCl, 50 ml every 6 h
Trial: 23982113
Drug: Omega-3 (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (1.8 g daily for 12 weeks)
Trial: 19683191
Drug: Betaxolol 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 0.25% (twice daily)
Trial: 19683191
Drug: TGFS 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGFS 0.25% (daily)
Trial: 19683191
Drug: TGFS 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGFS 0.5% (daily)
Trial: 8913399
Drug: Ceftriaxone 500
RxNorm normalized name: ceftriaxone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 500 mg in 2 mL of lidocaine 1% solution (250 mg/mL)
Trial: 8913399
Drug: Ceftriaxone 500
RxNorm normalized name: ceftriaxone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 500 mg in 1.4 mL of lidocaine 1% solution (350 mg/mL)
Trial: 1862788
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day desipramine
Trial: 1862788
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day amantadine-placebo
Trial: 30933317
Drug: Yoga during
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga during treatment
Trial: 30933317
Drug: Yoga post-treatment
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Yoga post-treatment
Trial: 27545747
Drug: Integrated Approach
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Approach of Yoga Therapy (IAYT)
Trial: 17566756
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 830 and 633nm LED phototherapy
Trial: 17566756
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment light
Trial: 26442394
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 0.5 mg.kg(‐1)